Concurrent inhibition of CDK2 adds to the anti-tumour activity of CDK4/6 inhibition in GIST.
Inga-Marie SchaeferMatthew L HemmingMeijun Z LundbergMatthew P SerrataIsabel GoldaracenaNinning LiuPeng YinJoao A PauloSteven P GygiSuzanne GeorgeJeffrey A MorganMonica M BertagnolliEwa T SicinskaChen ChuShanshan ZhengAdrian Mariño-EnriquezJason L HornickChandrajit P RautWen-Bin OuGeorge D DemetriSinem K SakaJonathan A FletcherPublished in: British journal of cancer (2022)
These studies establish the biological rationale for CDK2 and CDK4/6 co-inhibition as a therapeutic strategy in patients with advanced GIST, including metastatic GIST progressing on tyrosine kinase inhibitors.